Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders

Hemab Raises US$ 55M Series A to Advance Next Generation Therapeutics for Bleeding and Thrombosis Disorders

• Benny Sorensen appointed Chief Executive Officer and Co-Founder Johan Henrik Faber appointed Chief Technology Officer
• Financing led by Novo Holdings, HealthCap and RA Capital Management
• Advancing pipeline of bispecific and monoclonal antibodies with prophylactic potential to avoid life-threatening bleeds

·         Aim to rapidly target multiple rare bleeding indications

Copenhagen, Denmark and Boston, US – 22 July 2021 – Hemab ApS (“Hemab”), a biotech company developing next generation therapeutics for serious underserved bleeding and thrombosis disorders, today announces the successful closing of a US$ 55M Series A financing. The investment was led by Novo Holdings, HealthCap and RA Capital Management.

Benny Sorensen, MD, PhD, who served on Hemab’s Board of Directors, has been appointed Chief Executive Officer and will be based in the US. Dr Sorensen brings a wealth of patient-centred R&D experience in many therapeutic areas including thrombosis and hemostasis. Until recently, Dr Sorensen served as Head of Clinical Development at Codiak BioSciences and has moved to be on its Scientific Advisory Board. Hemab’s co-founders Johan Henrik Faber, who held leadership positions within hemophilia drug research and development at Novo Nordisk, has been appointed Chief Technology Officer; Søren Bjørn, has been appointed Scientific Advisor; and Thomas Batchelor joins the Board of Directors.

Proceeds from the financing will be used to progress the Company’s promising pipeline of monoclonal and bispecific antibody-based therapeutics into later stages of development. The pipeline will initially focus on underserved people living with rare bleeding disorders such as Glanzmann’s Thrombasthenia (GT), with plans to expand into more common disorders of hemostasis and thrombosis. The financing will also enable Hemab to further build the team and expand its operational footprint in Denmark and the US.

Benny Sorensen, MD, PhD, Chief Executive Officer of Hemab, said: “We are very pleased to welcome high profile international life sciences investors Novo Holdings, HealthCap and RA Capital Management. This financing will enable us to accelerate the development of innovative therapeutics for long underserved patients with serious bleeding and thrombosis disorders. Despite the innovations seen in treatments for hemophilia A and B in the last five decades, treatments for other rare bleeding disorders such as, for example GT, are still limited to blood transfusions and acute treatments. We owe these patients new treatment options and Hemab is uniquely positioned to leapfrog drug development of these medicines and bring treatment paradigms into the 21^st century.”

Johan Henrik Faber, MSc, PhD, Co-Founder and Chief Technology Officer of Hemab, said: “As founders, we are thrilled to reach this important milestone. Benny is an extraordinary leader and an expert in clinical drug development in hemophilia, which is exactly what Hemab needs to secure clinical proof of concept for our lead candidate. Novo Holdings, HealthCap and RA Capital Management share our vision for the Company and we look forward to advancing Hemab’s preclinical portfolio with this team.”

As a result of the financing, Mårten Steen, Partner at HealthCap and Laura Tadvalkar, Principal at RA Capital Management, will join Jørgen Søberg Petersen, Partner at Novo Holdings and Hemab’s Chairman, Camilla Petrycer Hansen, Principal at Novo Seeds, and Thomas Batchelor on the Board of Directors.

Jørgen Søberg Petersen, Chairman of Hemab and Partner at Novo Holdings, said: “Novo Seeds is focused on creating and building world class companies that are developing innovative treatments for patients with unmet medical needs. We created Hemab just over six months ago and we are very pleased to announce this significant financing backed by top tier investors from the Nordics and the US. Hemab’s novel approach to effectively treat rare bleeding disorders lacking effective therapeutic options is unique and provides potential for a breakthrough therapy across several underserved hematological diseases. I am looking forward to continuing the successful collaboration with Benny, Johan and the Hemab team.”

Mårten Steen, Partner at HealthCap, said: “We are excited to invest in Hemab, a company that fits HealthCap’s strategy, addressing significant unmet medical needs with a strong platform and potential to generate many breakthrough therapeutics in the future.”

Laura Tadvalkar, Principal at RA Capital Management, said: “We believe Hemab’s innovative approach to addressing rare bleeding disorders has the potential to make an impactful difference for patients, and we are excited to support the Company through this financing as well as in expanding their operations in the US.”